172 related articles for article (PubMed ID: 29051736)
1. Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.
Chen W; Shui F; Liu C; Zhou X; Li W; Zheng Z; Fu W; Wang L
Front Pharmacol; 2017; 8():707. PubMed ID: 29051736
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.
Chen W; Shui F; Liu C; Zhou X; Li W; Zheng Z; Fu W; Wang L
Front Pharmacol; 2017; 8():890. PubMed ID: 29206243
[TBL] [Abstract][Full Text] [Related]
3. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
[TBL] [Abstract][Full Text] [Related]
5. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.
Cooper ME; Regnell SE
Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB
Iyer MR; Cinar R; Wood CM; Zawatsky CN; Coffey NJ; Kim KA; Liu Z; Katz A; Abdalla J; Hassan SA; Lee YS
J Med Chem; 2022 Feb; 65(3):2374-2387. PubMed ID: 35084860
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders.
Dvorácskó S; Herrerias A; Oliverio A; Bhattacharjee P; Pommerolle L; Liu Z; Feng D; Lee YS; Hassan SA; Godlewski G; Cinar R; Iyer MR
J Med Chem; 2023 Sep; 66(17):11985-12004. PubMed ID: 37611316
[TBL] [Abstract][Full Text] [Related]
8. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB
Hirsch S; Hinden L; Naim MB; Baraghithy S; Permyakova A; Azar S; Nasser T; Portnoy E; Agbaria M; Nemirovski A; Golomb G; Tam J
J Control Release; 2023 Jan; 353():254-269. PubMed ID: 36442615
[TBL] [Abstract][Full Text] [Related]
9. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
10. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
[TBL] [Abstract][Full Text] [Related]
11. Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity.
Han JH; Shin H; Rho JG; Kim JE; Son DH; Yoon J; Lee YJ; Park JH; Song BJ; Choi CS; Yoon SG; Kim IY; Lee EK; Seong JK; Kim KW; Kim W
Diabetes Obes Metab; 2018 Sep; 20(9):2179-2189. PubMed ID: 29740969
[TBL] [Abstract][Full Text] [Related]
12. Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist.
Muller T; Demizieux L; Troy-Fioramonti S; Buch C; Leemput J; Belloir C; Pais de Barros JP; Jourdan T; Passilly-Degrace P; Fioramonti X; Le Bon AM; Vergès B; Robert JM; Degrace P
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328343
[TBL] [Abstract][Full Text] [Related]
13. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
[TBL] [Abstract][Full Text] [Related]
14. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
15. Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice.
Khan N; Laudermilk L; Ware J; Rosa T; Mathews K; Gay E; Amato G; Maitra R
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):757-764. PubMed ID: 33860199
[TBL] [Abstract][Full Text] [Related]
16. A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.
Hjorth S; Karlsson C; Jucaite A; Varnäs K; Wählby Hamrén U; Johnström P; Gulyás B; Donohue SR; Pike VW; Halldin C; Farde L
Neuropharmacology; 2016 Feb; 101():519-30. PubMed ID: 25791528
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
Janero DR; Lindsley L; Vemuri VK; Makriyannis A
Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861
[TBL] [Abstract][Full Text] [Related]
18. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
20. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
